Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1652W HIGH $4.98
Volume
210.01 K
Value Traded
532.94 K
Short % Float
12.54%
Days to Cover
1.0
-11.23%Week
-7.63%1 Month
-33.03%3 Month
-60.97%6 Month
-97.38%5 Year
-98.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
33.43 M
EPS (TTM)
-0.88
P/E Ratio
-
Ent. Value
-49.83 M
Total Shares
48.29 M
Float Shares
46.92 M
Insiders
2.88%
Institutions
26.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
FLNA Catalyst Timeline
Dated clinical, regulatory and corporate events for Filana Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Filana Therapeutics, Inc.
71Total events
6Upcoming
17Tier-1 (high impact)
2006 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Filana Therapeutics management to participate in 2026 Maxim Growth Summit
▲Clinical Hold LiftedsimufilamIND
FDA lifts clinical hold on simufilam IND, enabling Phase 2a study in TSC-related epilepsy
TSC-related epilepsysource ↗
●PublicationsimufilamPresentation
Publication of Eilat XVIII proceedings in Epilepsia
TSC-related epilepsysource ↗
▼IP Litigation RulingIP / Competition
Securities litigation settlement funding paid into escrow
●Oral PresentationsimufilamPresentation
Presentation at Eilat XVIII conference in Madrid, Spain
TSC-related epilepsysource ↗
▲PublicationsimufilamPresentation
Publication of preclinical simufilam data in Epilepsia
Tuberous Sclerosis Complex (TSC)-related epilepsysource ↗
▲PublicationsimufilamPresentation
Publication of preclinical simufilam data in Epilepsia
TSC-related epilepsysource ↗
▼Program DiscontinuationCorporate
Phase out of Alzheimer's disease development program completed
Alzheimer's diseasesource ↗
▼Equity OfferingCorporate
Registered direct offering of common stock for $50 million gross proceeds
◆Management ChangeCorporate
Appointment of Christopher Cook as Senior Vice President and General Counsel
◆Timing GuidancesimufilamPresentation
12-month interim analysis of open-label simufilam expected Q4 2021
Alzheimer's diseasesource ↗
▲Interim AnalysissimufilamTrial
9-month interim analysis of open-label simufilam in mild-to-moderate Alzheimer's disease
Alzheimer's diseasesource ↗
◆Trial InitiationsimufilamTrial
Initiation of Phase 3 clinical program of simufilam
Alzheimer's diseasesource ↗
▲Manufacturing MilestonesimufilamCMC / Inspection
Drug supply agreement with Evonik for large-scale clinical-grade simufilam
Alzheimer's diseasesource ↗
▼Equity OfferingCorporate
Registered direct offering of common stock for gross proceeds of $200 million
◆Trial InitiationsimufilamTrial
Phase 3 program with simufilam scheduled for initiation Fall 2021
Alzheimer's diseasesource ↗
▲Interim AnalysissimufilamTrial
6-month interim analysis of open-label study shows positive results on cognition
Alzheimer's diseasesource ↗
▼Equity OfferingCorporate
Cassava Sciences announces proposed public offering of common stock
▲Oral PresentationsumifilamPresentation
Sumifilam Phase 2b results presented at CTAD 2020
Alzheimer's diseasesource ↗
▲Topline ReadoutsumifilamClinical Data
Phase 2b topline results: sumifilam improves CSF biomarkers and cognition
Alzheimer's diseasesource ↗
▲Full ResultssumifilamClinical Data
Final results of Phase 2b study of sumifilam in Alzheimer's disease
Alzheimer's diseasesource ↗
▲End Of Phase 2 MeetingsimufilamFDA Meeting
Successful End-of-Phase 2 meeting with FDA
Alzheimer's diseasesource ↗
▲Topline ReadoutsimufilamClinical Data
Positive results on CSF biomarkers in double-blind, randomized, placebo-controlled Phase 2b study
Alzheimer's diseasesource ↗
◆Oral PresentationPTI-125Presentation
Late Breaking Oral Communication at CTAD 2019
Alzheimer's diseasesource ↗
▲Topline ReadoutPTI-125Clinical Data
Phase 2a biomarker results: improvements in CSF and plasma biomarkers
Alzheimer's diseasesource ↗
●Quarterly UpdateCorporate
Pain Therapeutics changes name to Cassava Sciences, effective immediately
▼FDA Feedback ReceivedRemoxyFDA Meeting
FDA meeting feedback on REMOXY NDA; FDA denied errors, stated comparator data irrelevant, and required FOIA for additional data
pain (abuse-deterrent opioid)source ↗
◆Topline ReadoutPTI-125Clinical Data
Expect to conclude Phase IIa study and announce clinical results
Alzheimer's diseasesource ↗
▲Topline ReadoutsimufilamClinical Data
Positive results on CSF biomarkers in open-label Phase 2a study
Alzheimer's diseasesource ↗
▲Trial InitiationPTI-125Trial
Initiated Phase IIa study of PTI-125 in mild-to-moderate Alzheimer's disease
Alzheimer's diseasesource ↗
▲Oral PresentationPTI-125Presentation
Full Phase I results presented at CTAD Nov 2017
Alzheimer's diseasesource ↗
▲First Patient DosedsimufilamTrial
First-in-human study: simufilam safe and well-tolerated
Alzheimer's diseasesource ↗
▲First Patient DosedPTI-125Trial
First-in-human Phase I study completed in 2017
Alzheimer's diseasesource ↗
▲Trial InitiationTrial
Phase I safety study for metastatic melanoma recruiting patients in Israel
metastatic melanomasource ↗
◆FDA Feedback ReceivedOxytrexFDA Meeting
Discussing with NIDA whether to test Oxytrex in drug abusers
painsource ↗
◆Type B MeetingFDA Meeting
Expected meeting with FDA to discuss potential new treatment for hemophilia
hemophiliasource ↗
◆Enrollment CompleteRemoxyTrial
Anticipate completing pivotal Phase III study with Remoxy
pain (abuse-resistant opioid)source ↗
◆Pipeline PrioritizationCorporate
Announcement of new clinical development opportunity in Q4 2006
outside of pain managementsource ↗
Past FDA Catalysts and PDUFA Decisions
How FLNA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 45%
Micro Cap(rank 296 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| simufilam Small moleculeCompletedNCT04079803 | Alzheimer Disease | Phase 3 | COMPLETED | 1,088 | Mar 31, 2020 | ||||||
| PTI-125 Small moleculeCompletedNCT03748706 | Alzheimer Disease | Phase 2 | COMPLETED | 13 | May 8, 2019 | ||||||
| simufilam Small moleculeCompletedNCT06195319 | Absorption | Phase 1 | COMPLETED | 8 | Mar 27, 2024 | ||||||
| simufilam Small moleculeCompletedNCT06390410 | Hepatic Insufficiency | Phase 1 | COMPLETED | 27 | Dec 7, 2024 | ||||||
| PTI-125 Small moleculeCompletedNCT03784300 | Alzheimer Disease, Early Onset | Phase 1 | COMPLETED | 24 | Mar 27, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every FLNA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Barry RichardDirector, Officer (President & CEO) | Buy | 100,000 1,337,964 held | $0.92 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FLNA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in FLNA for Q2 2026. | ||||
FLNA Institutional Ownership Trends
FLNA Short Interest
Shares sold short, counted twice a month.
12.54%
Short % of Float
of tradable shares sold short
5.9M
Shares Sold Short
-5.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
9.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FLNA ranks across every disease it competes in
Competitive Position is a premium feature
See how FLNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFLNA News
FLNAFilana Therapeutics to Participate in the 2026 Maxim Growth Summit
Filana Therapeutics, Inc. will participate in the 2026 Maxim Growth Summit from October 12-14, 2026, in New York. The company's management team will engage in one-on-one meetings to discuss their innovative therapies for Tuberous Sclerosis Complex-related epilepsy. This participation underscores Filana's commitment to advancing its therapeutic developments and investor relations.
Read more →FLNA▲ +39.3%on this news
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Filana Therapeutics has received FDA approval to lift the clinical hold on simufilam, enabling the company to proceed with a Phase 2a study targeting TSC-related epilepsy. The trial will assess the safety and efficacy of simufilam in patients aged 12 to 55. Patient screening is anticipated to commence in early 2027, with a focus on addressing the challenges of drug-resistant epilepsy.
Read more →FLNAFilana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Filana Therapeutics reported its Q2 2026 financial results, highlighting a net loss of $8.6 million. The company is working to lift a clinical hold on its trial for TSC-related epilepsy and is actively engaging with the TSC community. Significant reductions in operational expenses were noted, and participation in the upcoming TSC World Conference is planned.
Read more →FLNA▼ -5.6%on this news· ran to -17% by day 3
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
Filana Therapeutics has reported its Q1 2026 financial results, highlighting progress in its TSC-related epilepsy program. The company is addressing an FDA Clinical Hold and has published promising preclinical data on simufilam. Despite a net loss of $10.3 million, Filana maintains a solid cash position with no debt.
Read more →FLNAFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
Filana Therapeutics presented its TSC-related epilepsy program at the Eilat XVIII conference in Madrid, focusing on simufilam's clinical development. The company aims to engage with the epilepsy community while addressing a clinical hold from the FDA. Updates on the program are expected in the coming months as they work to provide the necessary information to the FDA.
Read more →FLNAFilana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
Filana Therapeutics announced the publication of preclinical data in 'Epilepsia' demonstrating that simufilam effectively attenuates seizure progression in a mouse model of Tuberous Sclerosis Complex (TSC). The study confirms previous findings and highlights the potential of simufilam as a treatment for TSC-related epilepsy, which affects around 45,000 individuals in the U.S. The company is addressing FDA inquiries related to a clinical hold.
Read more →FLNA▼ -6.7%on this news
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Filana Therapeutics reported a net loss of $91 million for 2025, significantly higher than the previous year. The company is addressing FDA requests related to its TSC program and anticipates submitting a response soon. Despite the financial losses, Filana maintains a strong cash position and has reduced R&D expenses significantly.
Read more →FLNACassava Announces Closure of U.S. Department of Justice Investigation
Cassava Sciences, Inc. has announced the closure of a U.S. Department of Justice investigation. This development is expected to positively impact the company's reputation and investor confidence. The company focuses on developing treatments for central nervous system disorders, including Tuberous Sclerosis Complex-related epilepsy.
Read more →FLNACassava Announces Agreement to Settle Securities Class Action Litigation
Cassava Sciences, Inc. has announced a definitive agreement to settle a consolidated securities class action litigation for $31.25 million. This settlement, which does not imply any wrongdoing by the company, allows Cassava to refocus its efforts on the development of simufilam, an investigational treatment for TSC-related epilepsy. The settlement covers claims from stock purchasers between September 2020 and October 2023.
Read more →FLNACassava Sciences Announces $ 50 Million Registered Direct Offering of Common Stock AUSTIN, Texas, Nov. 18 , 20 2 2 – Cassava Sciences , Inc. (Nasdaq: SAVA ) (the “Company” or “Cassava
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock AUSTIN, Texas, Nov. 18, 2022 Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences ), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it
Read more →FLNACassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign AUSTIN, Texas – November 3 , 20 2 2 – Cassava Sciences , Inc. (Nasdaq: SAVA), a clinical-stage biot
Cassava Sciences Files Lawsuit Against Perpetrators of Short and Distort Campaign AUSTIN, Texas November 3, 2022 Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individual
Read more →FLNACassava Sciences Announces Expansion of Leadership Team · Chris Cook , A Skilled Litigator, To Join Management Team as General Counsel · New Position Is Expected to Be Critical to Operations and Strate
Cassava Sciences Announces Expansion of Leadership Team AUSTIN, Texas October 27, 2022 Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced the expansion of its leadership team with the appointment of Christopher
Read more →FLNAxFEFF; Encouraging Interim Results at 9 Months from an Open-Label Study of Simufilam in Patients with Alzheimer's Disease Lindsay H. Burns Tamara Doehner, John Puente, Brian Beck, Yaneicy Gonzalez Rojas, Evelyn Lopez-Bri
Encouraging Interim Results at 9 Months from an Open-Label Study of Simufilam in Patients with Alzheimer's Disease Lindsay H. Burns Tamara Doehner, John Puente, Brian Beck, Yaneicy Gonzalez Rojas, Evelyn Lopez-Brignoni, Boris Nikolov, Hoau-Yan Wang, Zhe Pei, Antonio Hernandez, Ca
Read more →FLNAxFEFF; Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer's Disease - Selection of Premier Research as CRO Marks Significant Milestone Toward Init
Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer's Disease - Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease - AUSTIN, Texas June 21, 2021
Read more →FLNAxFEFF; Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and
Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals AUSTIN, Texas June 14, 2021 Cassava Sciences, Inc. (Nasdaq: SAVA),
Read more →FLNAxFEFF; Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam AUSTIN, TX – March 9 , 2021 – Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam AUSTIN, TX March 9, 2021 Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, today announced it has entered into a drug suppl
Read more →FLNAxFEFF; Cassava Sciences Announces $ 200 Million Registered Direct Offering of Common Stock AUSTIN, Texas, Feb . 10 , 20 21 – Cassava Sciences, Inc. (Nasdaq: SAVA ) (the “Company” or “
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock AUSTIN, Texas, Feb. 10, 2021 Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences ), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that i
Read more →FLNAxFEFF; CASSAVA sciences We Focus on Alzheimer's disease February 2021 CASSAVA sciences 1 Forward-Looking Statements & Safe Harbor This presentation contains forward-looking statements, including statements made
CASSAVA sciences We Focus on Alzheimer's disease February 2021 CASSAVA sciences 1 Forward-Looking Statements & Safe Harbor This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation
Read more →FLNAxFEFF; Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company'
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company's Phase 3 development of simufilam for Alzheimer's disease. AUSTIN, TX Jan
Read more →FLNAxFEFF; Cassava Sciences Announces Proposed Public Offering of Common Stock AUSTIN, Texas, November 12 , 2020 – Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Science
Cassava Sciences Announces Proposed Public Offering of Common Stock AUSTIN, Texas, November 12, 2020 Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences ), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it is commen
Read more →About Filana Therapeutics, Inc.
Headquarters6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731
BIOPHARMAWATCH ELITE PLUS
Trade the next FLNA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime